ICON and Carnegie Mellon University Collaborate to Evaluate Patient-centric Informed Consent Processes
Dublin, Ireland, 23rd March 2015 – ICON plc, (NASDAQ: ICLR)a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it is sponsoring a series of research projects, led by Professor Baruch Fischhoff, Ph.D., at Carnegie Mellon University (CMU), to find new ways to improve information comprehension and retention by clinical trial participants. The research tools will include multimedia solutions from ICON’s Firecrest suite of products.
A leading authority on behavioural sciences in healthcare, Professor Baruch Fischhoff, Ph.D., is the Howard Heinz University Professor in the departments of Social and Decision Sciences and of Engineering and Public Policy at Carnegie Mellon University. A cognitive psychologist by training, Professor Fischhoff’s research focuses on risk communication, analysis and management, informed consent, security and environmental protection.
“We are looking into ways to help patients make well-informed decisions about whether to participate in clinical trials,” said Professor Fischhoff. “Our research will take advantage of advances in behavioural decision research and information technology to design and evaluate approaches for ensuring that patients understand the potential risks and benefits of joining trials.”
“Successful patient enrolment in clinical trials is dependent on an informed consent process that thoroughly and consistently explains the trial and instils trust in the patient,” commented Frances Abeton, VP Firecrest, at ICON plc. “The CMU research projects are designed to scientifically test, measure and validate what patients need in order to ensure truly informed consent. We also want to know how the presentation of clinical trial information affects patient understanding, confidence and trust.”
Following scientific peer review, the results of these studies will be accessible to the public and will influence the development of new ICON innovations, including a range of study management tools from Firecrest. Firecrest tools include investigator training, patient recruitment and retention services, eConsent, mobile data capture and an integrated patient and investigator portal, which greatly improve the compliance, consistency and quality of study-related activities by study personnel.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
